Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
PETALUMA, Calif., Oct. 26, 2017 -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that financial results for its fiscal second quarter 2018, ended September 30, 2017, will be released after the U.S. markets close on November 9, 2017. The earnings release will be followed by a conference call at 1:30 p.m. PST on November 9, 2017, to discuss fiscal second quarter results.
Individuals interested in participating in the conference call may do so by dialing 877-303-7607 for domestic callers or 973-638-3203 for international callers. Those interested in listening to the conference call live via the internet may do so at http://ir.sonomapharma.com/events.cfm.
A telephone replay will be available for seven days following the conclusion of the call by dialing 855-859-2056 for domestic callers, or 404-537-3406 for international callers, and entering conference code 85466211. A webcast replay will be available on the site at http://ir.sonomapharma.com/events.cfm for one year following the call.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
Dan McFadden
VP of Public and Investor Relations
(425) 753-2105
[email protected]
